• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Atypical responses to neoadjuvant chemotherapy combined with accelerated partial breast tumor-directed radiotherapy: two cases and considerations for future clinical trials.

作者信息

To Nhu Hanh, Kossai Myriam, Ouidir Nabila, Grellier Noemie, Assaf Elias, Gabelle-Flandin Isabelle, Belkacemi Yazid, Radosevic-Robin Nina

机构信息

Department of Radiation Oncology and The Henri Mondor Breast Center, The Henri Mondor University Hospital, Creteil, France.

University of Paris-Est Créteil (UPEC), Creteil, France.

出版信息

Rep Pract Oncol Radiother. 2022 Dec 29;27(6):1114-1118. doi: 10.5603/RPOR.a2022.0112. eCollection 2022.

DOI:10.5603/RPOR.a2022.0112
PMID:36632297
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9826652/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a196/9826652/6e35147353c1/rpor-27-6-1114f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a196/9826652/7b19b614a4b5/rpor-27-6-1114f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a196/9826652/6e35147353c1/rpor-27-6-1114f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a196/9826652/7b19b614a4b5/rpor-27-6-1114f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a196/9826652/6e35147353c1/rpor-27-6-1114f2.jpg

相似文献

1
Atypical responses to neoadjuvant chemotherapy combined with accelerated partial breast tumor-directed radiotherapy: two cases and considerations for future clinical trials.新辅助化疗联合加速部分乳腺肿瘤定向放疗的非典型反应：两例病例及对未来临床试验的思考
Rep Pract Oncol Radiother. 2022 Dec 29;27(6):1114-1118. doi: 10.5603/RPOR.a2022.0112. eCollection 2022.
2
Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.基于基因特征预测三阴性乳腺癌患者对新辅助化疗的反应。
Cancer Med. 2020 Sep;9(17):6281-6295. doi: 10.1002/cam4.3284. Epub 2020 Jul 21.
3
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.糖代谢改变影响三阴性及新辅助化疗乳腺癌的临床特征和预后。
Tumour Biol. 2016 Jun;37(6):8159-68. doi: 10.1007/s13277-015-4729-8. Epub 2015 Dec 29.
4
Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.三阴性乳腺癌对新辅助化疗的反应：Ki-67表达与病理反应之间的相关性
Asian Pac J Cancer Prev. 2016;17(2):807-13. doi: 10.7314/apjcp.2016.17.2.807.
5
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.新辅助多西他赛和阿霉素化疗治疗Ⅱ/Ⅲ期乳腺癌时临床病理参数的预后影响：三阴性乳腺癌的矛盾特征
BMC Cancer. 2007 Nov 1;7:203. doi: 10.1186/1471-2407-7-203.
6
Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.分泌型卷曲相关蛋白1（SFRP1）对三阴性乳腺癌新辅助化疗的影响不依赖于WNT信号通路。
Mol Cancer. 2014 Jul 17;13:174. doi: 10.1186/1476-4598-13-174.
7
Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer.三阴性乳腺癌新辅助化疗后p53表达的预后差异
Ann Surg Treat Res. 2020 Jun;98(6):291-298. doi: 10.4174/astr.2020.98.6.291. Epub 2020 May 28.
8
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.在三阴性乳腺癌（BrighTNess）中，将 PARP 抑制剂 veliparib 联合卡铂或卡铂单药添加到标准新辅助化疗中：一项随机、3 期试验。
Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.
9
Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?磁共振检查预测新辅助化疗后的病理完全缓解：HER2阳性和三阴性乳腺癌何时适用？
Breast Cancer. 2016 Sep;23(5):789-96. doi: 10.1007/s12282-015-0642-7. Epub 2015 Oct 5.
10
Monitoring the response to neoadjuvant chemotherapy in patients with breast cancer using ultrasound scattering coefficient: A preliminary report.使用超声散射系数监测乳腺癌患者新辅助化疗的反应：初步报告。
J Ultrason. 2019;19(77):89-97. doi: 10.15557/JoU.2019.0013. Epub 2019 Jun 28.

引用本文的文献

1
Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial.局部晚期乳腺癌对新辅助序贯放化疗的病理反应：来自法国Neo-APBI-01试验的初步转化结果
Cancers (Basel). 2023 Mar 29;15(7):2030. doi: 10.3390/cancers15072030.

本文引用的文献

1
Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss.电离辐射联合PARP1抑制剂可降低RB1/TP53缺失的前列腺癌的放射抗性。
Cancer Invest. 2021 May;39(5):423-434. doi: 10.1080/07357907.2021.1899200. Epub 2021 Mar 24.
2
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.联合 TP53 和 RB1 缺失促进前列腺癌对多种治疗药物的耐药性，并导致对复制应激的易感性。
Cell Rep. 2020 May 26;31(8):107669. doi: 10.1016/j.celrep.2020.107669.
3
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists.
优化放疗以增强乳腺癌的全身免疫反应：对乳腺癌放疗肿瘤学家的重要评价。
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):227-241. doi: 10.1016/j.ijrobp.2020.05.011. Epub 2020 May 14.
4
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.曲妥珠单抗-德鲁替康在 HER2 低表达晚期乳腺癌患者中的抗肿瘤活性和安全性：来自一项 Ib 期研究的结果。
J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14.
5
Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature.术前放疗：乳腺癌治疗的范式转变？文献回顾。
Crit Rev Oncol Hematol. 2019 Sep;141:102-111. doi: 10.1016/j.critrevonc.2019.06.003. Epub 2019 Jun 8.
6
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.新型 RB1 缺失转录组特征与多种癌症类型的不良临床结局相关。
Clin Cancer Res. 2019 Jul 15;25(14):4290-4299. doi: 10.1158/1078-0432.CCR-19-0404. Epub 2019 Apr 22.
7
Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy.接受新辅助化疗的乳腺癌患者化疗敏感性和预后的外周炎症/免疫指标
Onco Targets Ther. 2018 Mar 15;11:1423-1432. doi: 10.2147/OTT.S148496. eCollection 2018.
8
Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis.RB1 基因缺陷诱导的乳腺癌线粒体氧化磷酸化：对合成代谢、干性和转移的影响
Trends Cancer. 2017 Nov;3(11):768-779. doi: 10.1016/j.trecan.2017.09.002. Epub 2017 Oct 17.
9
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.三阴性乳腺癌：一种异质性疾病的挑战与机遇
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17.
10
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.p53和RB功能通路的同时失活预示着乳腺癌在体内对DNA损伤药物具有抗性。
Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.